Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: A retrospective multicenter study of 675 patients

Oncotarget

Volumn 5, Issue 13, 2014, Pages 4671-4682

  Helbling, Melina ^a   Lukesch, Anne ^b   Haimovici, Aladin ^a   Karamitopoulou, Eva ^a   Berger, Martin D ^b   Hädrich, Marion ^b   Mallaev, Makhmud ^b   Schnüriger, Beat ^b   Koelzer, Viktor H ^a   Dawson, Heather ^a   Borner, Markus ^c   Langer, Rupert ^a   Rosenberg, Robert ^d   Nitsche, Ulrich ^e   Inderbitzin, Daniel ^b,f   Lugli, Alessandro ^a   Tschan, Mario ^a   Zlobec, Inti ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Hospital Centre of Biel   (Switzerland)

^d Kantonsspital Baden   (Switzerland)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f Spital Bern Tiefenau   (Switzerland)

Author keywords

CD8; Colorectal cancer; IL 23; Prognosis

Indexed keywords

INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 23P40; UNCLASSIFIED DRUG; IL23R PROTEIN, HUMAN; INTERLEUKIN 12P40; INTERLEUKIN RECEPTOR;

ADENOMA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL MEMBRANE; CELL NUCLEUS; CELLULAR DISTRIBUTION; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR INVASION; VERY ELDERLY; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE COURSE; GENETICS; HEK293 CELL LINE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; TISSUE MICROARRAY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELL MEMBRANE; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYTOPLASM; DISEASE PROGRESSION; FEMALE; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-23 SUBUNIT P19; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, INTERLEUKIN; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS;

EID: 84904965484     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2069     Document Type: Article

References (26)

1. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J and Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol. 2010; 2010.
2. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F and Maloy KJ. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006; 203(11):2473-2483.
3. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA and Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006; 116(5):1310-1316.
4. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA and Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201(2):233-240.
5. Li Y, Chu N, Hu A, Gran B, Rostami A and Zhang GX. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain. 2007; 130(Pt 2):490-501.
6. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD and Cua DJ. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003; 198(12):1951-1957.
7. Yu H, Kortylewski M and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007; 7(1):41-51.
8. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA and Oft M. IL-23 promotes tumour incidence and growth. Nature. 2006; 442(7101):461-465.
9. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2(10):737-744.
10. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H and Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003; 101(7):2620-2627.
11. Blatner NR, Mulcahy MF, Dennis KL, Scholtens D, Bentrem DJ, Phillips JD, Ham S, Sandall BP, Khan MW, Mahvi DM, Halverson AL, Stryker SJ, Boller AM, Singal A, Sneed RK, Sarraj B, et al. Expression of RORgammat marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med. 2012; 4(164):164ra159.
12. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012; 491(7423):254-258.
13. Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW, Roffler SR, Chiang BL, Lee CN, Wu CW and Tao MH. Antitumor and antimetastatic activity of IL-23. J Immunol. 2003; 171(2):600-607.
14. Karamitopoulou E, Zlobec I, Kolzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K and Lugli A. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol. 2013; 26(2):295-301.
15. Karamitopoulou E, Lugli A, Panayiotides I, Karakitsos P, Peros G, Rallis G, Patsouris ES, Terracciano L and Zlobec I. Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. Histopathology. 2010; 57(2):233-243.
16. Drecoll E, Nitsche U, Bauer K, Berezowska S, Slotta-Huspenina J, Rosenberg R and Langer R. Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. Int J Colorectal Dis. 2014.
17. Koelzer VH, Lugli A, Dawson H, Hadrich M, Berger MD, Borner M, Mallaev M, Galvan JA, Amsler J, Schnuriger B, Zlobec I and Inderbitzin D. CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. J Transl Med. 2014; 12(1):81.
18. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. Journal of Pathology. 2014; 232(2):199-209.
19. Dawson H, Galvan JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, Economou M, Hammer C, Lugli A and Zlobec I. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer. 2013.
20. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-146.
21. Stanilov N, Miteva L, Mintchev N and Stanilova S. High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma. Int J Colorectal Dis. 2009; 24(2):151-157.
22. Wang YQ, Ugai S, Shimozato O, Yu L, Kawamura K, Yamamoto H, Yamaguchi T, Saisho H and Tagawa M. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer. 2003; 105(6):820-824.
23. Shan BE, Hao JS, Li QX and Tagawa M. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. Cell Mol Immunol. 2006; 3(1):47-52.
24. Hao JS and Shan BE. Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother. 2006; 55(11):1426-1431.
25. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-337.
26. Petanidis S, Anestakis D, Argyraki M, Hadzopoulou-Cladaras M and Salifoglou A. Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-gamma. PLoS One. 2013; 8(9):e73616.